Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 2500-2503, October 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gauvreau, D.
Right arrow Articles by de Lamirande, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gauvreau, D.
Right arrow Articles by de Lamirande, G.

Purification of a Ribonuclease Inhibitor from Novikoff Hepatoma Supernatant Fraction1

D. Gauvreau2, C. Gagnon3 and G. de Lamirande4

Institut du Cancer de Montréal, Centre Hospitalier Notre-Dame, and Département de Biochimie, Université de Montréal, Montréal, Quebec, Canada

A comparison between the levels of ribonuclease inhibitor in normal rat liver and Novikoff hepatoma 105,000 x g supernatant fractions is reported. Novikoff hepatoma contained 61% less inhibitor per g of tissue or 39% less per mg protein than did normal rat liver.

A rapid and simple method that had been developed for the purification of rat liver ribonuclease inhibitor was applied to Novikoff hepatoma 105,000 x g supernatant fraction. The purification procedure led to a 121-fold increase in specific activity, with a yield of 49%. The molecular weight and inhibition curve of purified inhibitor were also determined and were found to be similar to those of normal rat liver ribonuclease inhibitor.

1 This investigation was supported by grants from the National Cancer Institute of Canada, Le Ministère des Affaires Sociales du Québec, La Fondation J. H. Biermans, and Les Fondations J. Rhéaume.

2 Recipient of a studentship from l'Institut du Cancer de Montréal.

3 Recipient of a studentship from the Medical Research Council of Canada.

4 Research Associate of the National Cancer Institute of Canada.

Received 3/18/74. Accepted 6/ 5/74.




This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
M. C. Haigis, E. L. Kurten, and R. T. Raines
Ribonuclease inhibitor as an intracellular sentry
Nucleic Acids Res., February 1, 2003; 31(3): 1024 - 1032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.